MedTrace Logo

UK Registry for Baroreflex Activation Therapy

NCT03730519 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-06-08

No results posted yet for this study

Summary

This study is a post-marketing open label single arm, single centre clinical trial of electrical carotid sinus stimulation with the Barostim Neo device to target sub-optimally controlled arterial hypertension or highly variable blood pressure in patients for whom no alternative therapies are available.

Conditions

  • Baroreflex Failure Syndrome
  • Hypertension, Resistant to Conventional Therapy

Interventions

DEVICE

Baroreflex Activation Therapy with Barostim Neo

Baroreflex activation therapy (BAT) delivers electrical field stimulation at the carotid sinus to lower BP.

Sponsors & Collaborators

  • CVRx, Inc.

    collaborator INDUSTRY

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Melvin D Lobo, MBChB PhD · Queen Mary University of London

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2021-11-01
Completion
2021-11-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03730519 on ClinicalTrials.gov